Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

C.CGN , NERV , PMN , KLTO , JUNS , VIGL , ANRO
Sort by: Date|Relevance

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. Early this morning, clinical-stage biopharmaceutical company Alder BioPharmaceu...
Streetwise Reports | September 17, 2019 |

BioNTech, Evotec, XPhyto - will the next rally start?

Germany's leading index DAX closed the previous day at 11,391 points, its highest level since March 2020. At the beginning of the week the index of the 30 largest German companies gained 317 points compared to Friday, representing a gain of 2.87%. In the USA Wall Street remain...
Mario Hose | May 26, 2020 |

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also anno...
Streetwise Reports | October 23, 2019 |

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. Neurodegen...
Streetwise Reports | December 9, 2019 |

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

An Emerging Medical Market Play with Great Opportunity

(Image via Bioasis Technologies Inc.) Biopharmaceutical Company Bioasis Technologies Inc. ( TSX-V: BTI , OTCQB: BIOAF , Forum ) is developing its proprietary xB 3TM platform technology to deliver therapeutics across the blood brain barrier (BBB) and int...
Stockhouse Editorial | July 28, 2020 |

A ‘Novel’ Investment In Psychedelic-Inspired Medicines

Stockhouse investors are keenly aware of the booming trend in the psychedelic healthcare space…in many ways the new Cannabis 2.0 over the last 12 – 24 months. Capital markets have taken to them en masse – a market now estimated to be in excess of USD$5 billion and expected ...
Dave Jackson | April 16, 2021 |